-transparent.png){kind=logo}
CC-1065 was found to cause delayed toxicity at therapeutic doses, therefore, a large number of analogs have since been synthesized. A series of analogs with simplified but closely related structures were chosen for this investigation because some were found to be superior to CC-1065 in the treatment of several experimental tumors. The inhibition of L1210 cell growth by U-68,415 was comparable to that by CC-1065. A similar situation was true in terms of their in vivo potency; however, U-68,415 was superior to CC-1065 in terms of anti-P388 leukemia activity. At the optimal dosage, U-68,415 produced 4 out of 6 long-term (greater than 30 day) survivors; whereas CC-1065 produced a mere 62% increase of life span (ILS) and no long-term survivors. The order of antitumor potency and effectiveness of the CC-1065 analogs was U-68,415 greater than U-66,694 greater than U-68,819 greater than U-66,664, which was parallel to the inhibition of L1210 cell growth. CC-1065 and all the analogs tested here inhibited DNA synthesis approximately 10 times more than RNA synthesis. Protein synthesis was the least inhibited. On a molar basis, U-68,415 was about 6-9 times more inhibitory toward cellular DNA synthesis than CC-1065, yet the interaction and/or binding of CC-1065 to DNA determined by circular dichroism, DNA melting or differential cytotoxicity assay was much stronger than that of U-68,415.(ABSTRACT TRUNCATED AT 250 WORDS)
L H Li, and
T L Wallace, and
T F DeKoning, and
M A Warpehoski, and
R C Kelly, and
M D Prairie, and
W C Krueger
January 1986,
Advances in enzyme regulation,
L H Li, and
T L Wallace, and
T F DeKoning, and
M A Warpehoski, and
R C Kelly, and
M D Prairie, and
W C Krueger
January 1991,
Chemico-biological interactions,
L H Li, and
T L Wallace, and
T F DeKoning, and
M A Warpehoski, and
R C Kelly, and
M D Prairie, and
W C Krueger
May 1988,
Biochemical pharmacology,
L H Li, and
T L Wallace, and
T F DeKoning, and
M A Warpehoski, and
R C Kelly, and
M D Prairie, and
W C Krueger
January 1988,
Chemico-biological interactions,
L H Li, and
T L Wallace, and
T F DeKoning, and
M A Warpehoski, and
R C Kelly, and
M D Prairie, and
W C Krueger
June 1985,
The Journal of antibiotics,
L H Li, and
T L Wallace, and
T F DeKoning, and
M A Warpehoski, and
R C Kelly, and
M D Prairie, and
W C Krueger
January 1991,
Chemico-biological interactions,
L H Li, and
T L Wallace, and
T F DeKoning, and
M A Warpehoski, and
R C Kelly, and
M D Prairie, and
W C Krueger
October 2009,
Journal of medicinal chemistry,
L H Li, and
T L Wallace, and
T F DeKoning, and
M A Warpehoski, and
R C Kelly, and
M D Prairie, and
W C Krueger
January 1983,
Advances in prostaglandin, thromboxane, and leukotriene research,
L H Li, and
T L Wallace, and
T F DeKoning, and
M A Warpehoski, and
R C Kelly, and
M D Prairie, and
W C Krueger
April 1996,
The Journal of antibiotics,
L H Li, and
T L Wallace, and
T F DeKoning, and
M A Warpehoski, and
R C Kelly, and
M D Prairie, and
W C Krueger
January 1993,
Peptide research,
